Through the partnership, ProvideGx will supply hospitals with amiodarone and sterile water. Amiodarone is used to manage late-onset cardiac arrest and ventricular arrhythmia, two common complications associated with hospitalized COVID-19 patients. Sterile water is used to reconstitute many injectable drugs, including remdesivir, which has been shown to shorten recovery time for COVID-19 patients.
Amiodarone isn’t on the FDA’s shortage list, but Premier’s purchasing data shows it is heavily backordered, with just 55 percent of orders being fulfilled due to a dramatic spike in demand during the first quarter of 2020. Premier said it is able to use its ProvideGx program, which includes 1,600 hospitals in the U.S., to look at historic purchasing trends and make predictions about drugs that may be vulnerable to shortages.
Sterile water is on the American Society of Health-System Pharmacists’ shortage list.
“When it comes to the COVID-19 response, we can’t afford to delay action until drugs roll onto the FDA shortage list,” said Premier President Michael Alkire. “By that time, patient care is already compromised.”
Read the full news release here.
More articles on pharmacy:
6 BCBS companies sue CVS, claiming decadelong insurance fraud scheme
FDA finds carcinogen in popular diabetes drug
Georgia pharma company recalls thyroid drug for super potency
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.